Endovascular Treatment of 300 Consecutive Middle Cerebral Artery Aneurysms: Clinical and Radiologic Outcomes


AJNR Am J Neuroradiol 2014, 35 (4) 706-714
doi: https://doi.org/10.3174/ajnr.A3776
http://www.ajnr.org/content/35/4/706

This information is current as of October 29, 2023.
Endovascular Treatment of 300 Consecutive Middle Cerebral Artery Aneurysms: Clinical and Radiologic Outcomes


ABSTRACT

BACKGROUND AND PURPOSE: There is controversy as to the best mode of treating MCA aneurysms. We report the results of a large endovascular series of patients treated at our center.

MATERIALS AND METHODS: This study was a retrospective analysis of a prospectively acquired database. All patients with saccular MCA aneurysms treated between November 1996 and June 2012 were included. World Federation of Neurosurgical Societies grade, aneurysm site, size, and aneurysm neck size were recorded, along with clinical outcome assessed with the Glasgow Outcome Scale and radiographic occlusion assessed with the Raymond classification at 6 months and 2.5 years.

RESULTS: A total of 295 patients with 300 MCA aneurysms were treated including 244 ruptured aneurysms (80.7%). The technical failure rate was 4.3% (13 patients). Complete occlusion or neck remnant was achieved in 264 (91.4%). Complications included rupture in 15 patients (5%), thromboembolism in 17 patients (5.7%), and early rebleeding in 3 patients (1%). Overall permanent procedural-related morbidity and mortality were seen in 12 patients (7.8%). Of the ruptured aneurysms, 189 (79.4%) had a favorable clinical outcome (Glasgow Outcome Scale score, 4–5). A total of 33 patients (13.6%) died. On initial angiographic follow-up, aneurysm remnant was seen in 18 aneurysms (8.1%). A total of 13 patients (4.3%) were retreated.

CONCLUSIONS: Our experience demonstrates that endovascular treatment of MCA aneurysms has an acceptable safety profile with low rates of technical failure and re-treatment. Therefore, coiling is acceptable as the primary treatment of MCA aneurysms.

ABBREVIATIONS: EVC = endovascular coiling; GOS = Glasgow Outcome Scale; ISAT = International Subarachnoid Aneurysm Trial; WFNS = World Federation of Neurosurgical Societies

The International Subarachnoid Aneurysm Trial (ISAT) demonstrated an absolute 6.9% reduction in the rate of death or dependency at 1 year for patients treated with endovascular coiling (EVC). ISAT did not, however, address the specific issue of patients with MCA aneurysms, who represented only 303 (14.1%) of the 2143 enrolled patients. This has resulted in controversy as to the best mode of treatment of aneurysms at this location. Surgical clipping remains the standard treatment in many institutions. The anatomic location aids surgical access, and in some cases, surgery facilitates hematoma evacuation. There is also a perceived increased risk for EVC at this site because these aneurysms are often wide-neck and have branches arising from the neck. Recently, several surgical series have been published that demonstrate excellent clinical results with low rates of morbidity and mortality. Therefore, we analyzed the strategy at our institution where EVC is the first-line therapy for aneurysm treatment at any location and focused on the more controversial MCA aneurysms.

MATERIALS AND METHODS

Patient Population

This was an observational, prospectively collated study of 295 consecutive patients referred to our institution for endovascular treatment of ruptured and unruptured MCA aneurysms. All patients underwent primary EVC during a 15.5-year period (between November 1996 and June 2012). All patients with SAH were considered for EVC as the primary treatment technique when a consultant interventional neuroradiologist was available. Elective cases were discussed at our institutional neurovascular multidisciplinary meeting. Patients with fusiform or dissecting aneurysms and those treated with primary parent vessel occlusion were excluded from this study. Patient information, aneurysm characteristics, details of treatment,
and clinical course were entered prospectively into a data base and subsequently analyzed.

SAH was confirmed by cranial CT or lumbar puncture and CSF analysis. Of those with unruptured aneurysms, 21 patients with 23 aneurysms had previous SAH and delayed treatment of additional MCA aneurysms or SAH that was clearly the result of another aneurysm, with the additional MCA aneurysm treated in the same procedure. Thirty-two patients with 33 MCA aneurysms diagnosed incidentally were also treated.

Endovascular Procedure
All procedures were performed by consultant interventional neuroradiologists (S.A.R., M.D.B., and A.J.M. with 5, 3, and 20 years of endovascular experience when they started coiling patients within the study period, respectively). EVC was performed by use of conventional techniques with the patients under general anesthesia and systemic heparinization. A bolus of 3000–5000 IU of heparin was followed by continuous infusion via the catheter-flushing system at a concentration of 5 IU/mL. The aim was to place coils sequentially into the aneurysmal sac to the point of angiographic occlusion. Most coils deployed were bare platinum (Boston Scientific, now Stryker, Kalamazoo, Michigan; Micrus, now Codman Neurovascular, Raynham, Massachusetts; ev3, now Covidien, Dublin, Ireland). After diagnostic angiography, the aneurysm was selectively catheterized with a microcatheter by use of standard techniques, through a guide catheter positioned in the internal carotid artery.

Where necessary, balloon remodeling (12 cases primary treatment, 4 cases re-treatment) and stent-assisted coil embolization (1 case primary treatment, 1 case re-treatment) were used for the treatment of wide-neck aneurysms. Intravenous aspirin (500 mg) was used as a prophylaxis to prevent thromboembolic complications in both ruptured and unruptured aneurysms, administered after initial coil deployment when a degree of protection had been attained. Intravenous aspirin was also administered if a stent was deployed. Technical failure was defined as an attempted embolization procedure during which coils could not be deployed safely. Any procedural or other subsequent complication was recorded in addition to any deterioration in the patient’s neurologic status after the procedure. Craniotomy and hematoma evacuation or decompressive hemicraniectomy were performed to manage hematoma/herniation, after coil embolization.

Aneurysms Treated
The aneurysm responsible for hemorrhage was identified by blood distribution on CT, aneurysm appearance, and vasospasm distribution. This aneurysm was treated first. Additional aneurysms were treated during the same procedure or after recovery from hemorrhage. If it was not possible to clearly identify the ruptured aneurysm, all possible candidates were treated initially, and aneurysms were classified as ruptured. If contralateral aneurysms were treated at a later date, these were classified as unruptured.

Clinical and Radiologic Follow-Up
Clinical outcome was independently obtained for all at a 3- to 6-month clinic visit with a specialist neurovascular nurse practi-
ruptured aneurysms underwent primary surgical clipping. A total of 36 patients were treated with primary clipping because of either lack of availability of an interventional neuroradiologist or if the patient was being treated by a vascular neurosurgeon (most aneurysms were clipped before 2003). Eight aneurysms were clipped because of anatomic considerations after angiography. In 13 cases, the patients were treated with clipping after attempted coil- ing. In the same period, 16 patients with unruptured MCA aneu-rysms were treated with elective primary clipping. The indications were patient choice or difficult aneurysmal morphologic features.

Procedural Success
Initial coiling results are summarized in Table 2. Technical failure was seen in 13 aneurysms (5 unruptured and 8 ruptured), equating to 4.3% of treated aneurysms. These patients went on to have microsurgical clipping. A total of 215 aneurysms were completely occluded on initial conventional angiography (71.7%), and neck remnant was seen in 59 patients (19.7%), resulting in a rate of satisfactory occlusion of 91.4%. An aneurysmal remnant was seen in 9 patients (3%). In 2 patients, a complication precluded EVC.

Complications
Complications and clinical outcome are summarized in Table 3. The technical complication rate was 12.9%, including aneurysmal perforations and thromboembolic events with either silent or transient symptoms. The overall permanent procedural-related morbidity rate was 3.8% (11 patients) and mortality rate was 4% (12 patients), equating to a permanent morbidity and mortality rate of 7.8% (23 patients). Of those patients who experienced a technical complication, 26 (68.4%) of 38 had a favorable outcome (GOS, 4 or 5). When unruptured aneurysms were considered separately, 1 patient had transient arm weakness that fully resolved and 1 patient (1.8%) died as a result of aneurysmal perforation, but no other permanent complications were encountered.

Aneurysmal Perforation. Fifteen patients (5% of procedures) had intraoperative aneurysmal perforations. In 10 patients, the perforation occurred during coil insertion. In 1 patient, the perforation was secondary to remodeling balloon inflation; in another patient, perforation was secondary to contrast injection before intervention. When rupture occurred, heparin was reversed immediately with protamine; coiling continued to limit the extent of hemorrhage and occlude the aneurysm; and measures were used, if necessary, to reduce intracranial pressure via ventricular drainage of CSF. Six ruptures were clinically silent. Three patients died after rupture; 12 had an independent outcome (GOS, 4–5).

Thromboembolic Events. Eighteen patients (6% of procedures) experienced thromboembolic complications. These were man- aged by intravenous aspirin and abciximab and induced hypotension. Of these thromboembolic complications, 6 were clinically silent and 3 were transient. Twelve patients were independent (GOS, 4–5), and 6 patients died.

Rebleeds. Three patients (1.2%) experienced early rebleeds. All occurred within 24 hours of the procedure, and 3 patients died.

Other Complications. Coil protrusion was noted in 2 patients with no clinical sequelae.

Clinical Outcome
Of the patients with ruptured aneurysms, 79.8% had a favorable clinical outcome (GOS, 4–5). A total of 33 patients (13.6%) died (Table 4). One of 53 patients with an unruptured aneurysm died as a result of procedural rupture and was the only patient who experienced a permanent change in neurologic status as a result of the procedure. Of the patients who underwent a craniotomy or craniectomy for management of hematoma or mass effect, 8 (40%) of 20 achieved a clinical outcome of GOS 4. The mortality rate was 45% in this subgroup.

Anatomic Outcome
Initial follow-up (mean, 7 months; range, 3–17 months) was available in 219 patients. Allowing for those patients who died, follow-up was available in 84%. Reasons for no follow-up included a dead or severe outcome in 38 patients, advanced age in 12 patients, microsurgical clipping as a definitive treatment in 13 patients, patient choice in 7 patients, and unknown reasons in 6 patients.

Medium- to long-term follow-up (mean, 35 months; range, 18–108 months) was available in 158 patients. Twenty-two patients were ineligible because they were due this follow-up beyond the study period. Therefore, medium- to long-term follow-up was available in 80% of patients who had undergone initial follow-up.
Table 5: Angiographic outcomes at initial follow-up

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Complete Occlusion</th>
<th>Neck Remnant</th>
<th>Aneurysm Remnant</th>
<th>Re-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>All aneurysms (n = 219)</td>
<td>148 (67.6%)</td>
<td>53 (23.3%)</td>
<td>18 (8.1%)</td>
<td>13 (5.9%)</td>
</tr>
<tr>
<td>Ruptured aneurysms (n = 175)</td>
<td>117</td>
<td>42 (23.9%)</td>
<td>16 (8.0%)</td>
<td>13 (5.1%)</td>
</tr>
<tr>
<td>Unruptured aneurysms (n = 44)</td>
<td>31</td>
<td>11 (24.4%)</td>
<td>2 (4.5%)</td>
<td>0</td>
</tr>
<tr>
<td>Small (≤10 mm)</td>
<td>137</td>
<td>26 (19.0%)</td>
<td>11 (8.0%)</td>
<td>6 (4.3%)</td>
</tr>
<tr>
<td>Large (11–24 mm)</td>
<td>9</td>
<td>26 (28.8%)</td>
<td>6 (6.6%)</td>
<td>6 (6.6%)</td>
</tr>
<tr>
<td>Giant (≥25 mm)</td>
<td>2</td>
<td>1 (50.0%)</td>
<td>1 (50.0%)</td>
<td>1 (50.0%)</td>
</tr>
<tr>
<td>Wide-neck (≥4 mm)</td>
<td>29</td>
<td>24 (82.8%)</td>
<td>10 (50.0%)</td>
<td>7 (29.8%)</td>
</tr>
</tbody>
</table>

and in 66% of the patients who were eligible for late follow-up and had survived the acute episode. Reasons for halting anatomic follow-up after initial follow-up were advanced age in 17 patients, out-of-region follow-up in 5 patients, patient choice in 12 patients, death from unrelated cause in 3 patients, and unknown reasons in 2 patients.

Initial angiographic follow-up is summarized in Table 5. Complete occlusion was seen in 148 aneurysms (67.6%), a neck remnant was seen in 53 (23.3%), and an aneurysmal remnant was seen in 18 aneurysms (8.1%). Stable or improved appearances were seen in 178 (81.3%) of 219 aneurysms. Twenty-three (10.5%) showed minor anatomic deterioration to the neck remnant but remained satisfactorily occluded. Of those aneurysms with complete occlusion at postcoiling angiography undergoing initial follow-up (n=164), the probability of complete occlusion was 84.1% (138 aneurysms), of a neck remnant was 12.2% (20 aneurysms), and of an aneurysmal remnant was 3.6% (6 aneurysms). Of those aneurysms with a neck remnant at postcoiling angiography undergoing initial follow-up (n=47), the probability of complete occlusion was 19.2% (9 aneurysms), of a neck remnant was 70.2% (33 aneurysms), and of an aneurysmal remnant was 10.6% (5 patients).

A total of 18 aneurysms (8.1%) showed an aneurysmal remnant at initial follow-up, 6 had shown a similar aneurysmal remnant on immediate postcoiling angiography, and 12 aneurysms demonstrated deterioration from complete occlusion or a neck remnant to an aneurysmal remnant. Aneurysmal remnants were more common in patients with large and giant aneurysms compared with small aneurysms at follow-up (15.6% vs 6.3%; P = .04). Wide-neck aneurysms were also significantly more common in patients who showed an aneurysmal remnant at follow-up compared with those with complete occlusion (19.6% vs 55.6%; P < .001). There were 13 (4.3%) of these patients who were retreated (12 with further coiling and 1 with microsurgery). The remaining 5 patients showed a stable aneurysmal remnant and were treated conservatively.

A total of 158 patients underwent long-term follow-up: 110 patients (69.4%) showed complete occlusion, 43 (27.4%) showed a neck remnant, and 5 (3.1%) showed an aneurysmal remnant. A total of 150 (95%) patients, including the re-treated patients, showed stable appearances. A new neck remnant that did not warrant re-treatment was seen in 7 patients, and new aneurysmal remnant was seen in only 1 patient.

Re-Treatment

Twelve of 13 recurrent aneurysms were re-treated (4.3% of all aneurysms) with coil embolization and 1 with microsurgical clipping. One of 12 endovascular patients required 4 additional treatments for a recurrent, large, wide-neck aneurysm; she refused surgery. Subsequent angiographic follow-up was available in these patients, and 5 achieved complete occlusion (including 1 patient who underwent microsurgery), 4 showed a neck remnant, and 4 showed a residual aneurysm. Stent or balloon-assisted coiling was used in 5 recurrent aneurysms. No morbidity or mortality was related to EVC.

**DISCUSSION**

Controversy has existed as to the best mode of therapy for MCA aneurysms. The anatomy of MCA aneurysms is often considered more favorable for surgical treatment because of the frequency of a wide-neck configuration with incorporation of MCA branches that are technically more challenging to treat by EVC. ISAT demonstrated that 116 (71.6%) of 162 endovascular patients and 100 (71.9%) of 139 surgical patients attained independence (mRS, 0–2); however, MCA aneurysms were relatively underrepresented in ISAT, owing to the absence of clinical equipoise at the time of recruitment. This has led to criticism of the practice of applying ISAT to MCA aneurysms and the generalized adoption of EVC for aneurysms at this location. We therefore review the clinical and radiologic outcomes of this series in the context of the endovascular and surgical literature.

**Clinical Outcome in Patients with Ruptured Aneurysms**

Favorable clinical outcomes (mRS, 0–2) for ruptured aneurysms at all locations in ISAT and CLARITY (Clinical and Anatomical Results in the Treatment of Ruptured Intracranial Aneurysms, a multicenter prospective study of consecutively coiled patients) were 76.3% and 72.3%, respectively, with the proportion of favorable presenting clinical grade patients (WFNS, 1–2) being 88% and 65.7%, respectively. Favorable clinical outcomes (mRS, 0–2 and GOS, 5) in other large series of ruptured MCA aneurysms comprising at least 50 patients treated with EVC, are within the 67%–85% range.

In the present study, the largest published single-center experience to date, patients with consecutive ruptured MCA aneurysms achieved good outcome (GOS, 5) in 70.3% and favorable outcome (GOS, 4 and 5) in nearly 80%, with the proportion of favorable presenting clinical grade patients (WFNS, 1–2) being 72%. We were able to directly compare the results of our present study to a large audit of ruptured aneurysms at all locations treated through EVC at our institution with similar distribution of clinical grade. In this study, 711 patients with 717 ruptured aneurysms were reviewed. In the 605 patients with aneurysms at all locations other than the MCA, favorable outcome (GOS, 4 and 5) was seen in 490 (80.9%). Mortality occurred in 89 patients (14.7%). Statistical comparison of clinical outcomes for patients with ruptured MCA aneurysms in the present study showed no significant difference in the favorable outcome (P = .58) or mortality (P = .69).

Other than the ISAT results, prospective data on outcomes for clipping of ruptured MCA aneurysms are lacking. In 1990, The International Cooperative Study on the Timing of Aneurysm Surgery, a multicenter prospective observational study, included 786 patients with ruptured MCA aneurysms. A total of 480 pa-
patients (61%) achieved good outcome (GOS, 5) at 6 months. Following this, Rinne et al. published one of the largest series of 561 patients with 690 MCA aneurysms, 91% presenting with SAH and 80% with Hunt and Hess grades I–III. Overall favorable outcome (GOS, 5) was 60%. Poor outcomes (GOS, 1–3) were seen in 32%, and this rate was higher in large or giant aneurysms. It is surprising to note that there were significantly more poor outcomes among patients with ruptured MCAs than among those with any other anterior circulation aneurysms (32% and 25%, respectively).

After ISAT, several single-center studies have been published. Güresir et al. treated 168 patients with ruptured MCA aneurysms. Favorable outcome (mRS, 0–2) was 55% at 6 months. At the other end of the scale, among 80 patients treated by Van Dijk et al., including 67% with WFNS grades I–II, 80% achieved an mRS of 0–2 at longer-term clinical follow-up (mean, 4.7 years). In one of the largest and most complete recent series, Rodríguez-Hernández et al. treated 282 ruptured MCA aneurysms with 78% of patients presenting with Hunt and Hess grades I–III; favorable outcomes (mRS, 0–2) were achieved in 70.2%.

These results are similar to those achieved in the present study by using EVC. Therefore, although the conservative view is that surgery should remain the treatment of choice of ruptured MCA aneurysms, except when there are extenuating comorbidities or overriding patient preferences, we believe that for the range of ruptured MCA aneurysms, at least equivalent clinical outcomes to the best surgical series can be obtained by use of conventional endovascular techniques.

**Coiling in the Presence of Intracerebral Hematoma**

One of the traditional advantages of a clipping strategy is that it allows hematoma evacuation. An alternative approach is to protect the aneurysm before evacuation through coiling. It is possible that this approach is more advantageous because hematoma evacuation in the presence of an unprotected aneurysm may initiate intraprocedural rupture. Furthermore, clipping may require a more extensive surgical exposure to access the aneurysm, perhaps involving retraction of contused parenchyma, which can result in edema or ischemia; this would no longer be required. By use of this approach in the present series, of 20 patients with WFNS grades III or higher (14/20 were grades IV and V), 40% of patients achieved an outcome of GOS 4. Other small series have also achieved more impressive outcomes in poor-grade patients by using this approach.

**Technical Success**

The coiling procedure was successfully performed in 94.4% of aneurysms with posttreatment imaging, demonstrating that 71.7% were completely occluded and 19.7% exhibited a neck remnant, equating to a satisfactory occlusion rate of 91.4%. The technical failure rate was 4.3%. These results are very similar to the results of a systematic review of 12 series comprising a total of 1030 patients with 1076 MCA aneurysms (500 patients had ruptured aneurysms, and 541 had unruptured aneurysms). In that study, the EVC failure rate was 4.8% (95% CI, 3.7%–6.3%). Overall, 82.4% (95% CI, 80.0%–84.6%) of MCA aneurysms were completely or nearly completely occluded at immediate postoperative angiographic follow-up, and 12.7% (95% CI, 10.9%–14.9%) were incompletely occluded. Prospective data specifically for MCA aneurysms are available from the results of the ATENA (Analysis of Treatment by Endovascular Approach of Nonruptured Aneurysms) study, which included 86 unruptured MCA aneurysms. Complete occlusion was achieved in 69.4%, neck remnant in 19.4% (adequate occlusion in 88.8%), and aneurysmal remnant in 11.3%. In the CLARITY study, 105 MCA aneurysms were included. Complete occlusion was achieved in 45.7%, neck remnant in 39% (adequate occlusion in 84.7%), and aneurysmal remnant in 15.2%. It is important to note that though occlusion rates were lower in this study, the results did not differ significantly from other anterior circulation locations.

We hope that this case series dispels the contradictory conclusions of previous publications, suggesting that EVC is appropriate only in a minority of MCA aneurysms. Our experience, and the experience of others, concludes that EVC is feasible in most aneurysms.

**Short-Term Follow-Up**

Initial angiographic follow-up demonstrated satisfactory occlusion in 92% of aneurysms, with 8.1% showing residual aneurysm. A total of 81% of MCA aneurysms, most treated as part of a coil-first policy, were stable or showed improved appearances at initial angiographic follow-up. A systematic review of 748 MCA aneurysms treated by endovascular means also showed angiographic stability or progression to better obliteration in 81% of patients undergoing follow-up angiography. In the CLARITY study, of 53 patients undergoing midterm follow-up, 57.4% (95% CI, 44.8–69.3) showed stability or improved appearances and 42.6% (95% CI, 30.7–55.2) had shown some degree of anatomic worsening, but presumably, this was not significant in most because 77.9% (95% CI, 66.2–87.1) were classified as having adequate occlusion. Although the rate of anatomic worsening was higher in other studies, the rate was very similar to that at other anatomic locations and was not specific for MCA aneurysms.

**Adjunctive Therapies**

In this series, bare platinum coils were the mainstay of treatment during a long enrollment period, with many aneurysms treated by use of old-generation technology. The use of adjunctive devices such as stent placement or balloon remodeling was very infrequent, and intra-aneurysmal flow diverters were not used. This trend may explain the relatively low thromboembolic complication rate, but also lower rates of complete occlusion compared with some recently published series on use of adjunctive devices. Adjunctive devices have been used in 20.4% of other published MCA series, with the aim of obtaining complete occlusion to minimize the risk for subsequent hemorrhage.

A critical appraisal of the available literature has suggested that balloon assistance has a very similar safety profile to coiling without remodeling. In the CLARITY and ATENA studies, the use of a balloon was not associated with significantly increased rates of thromboembolic events or aneurysmal perforation but was associated with an increased rate of adequate postoperative occlusion. Vendrell et al. treated 63 MCA aneurysms with a balloon remodeling technique. It is interesting to note that they
found that though this technique allowed treatment of aneurysms with more complex morphologic features, it was associated with more recurrences in the long term than were treatments without balloon remodeling.

Stent assistance may lower recurrence and allow more complete treatment of more complex lesions. However, there are reservations regarding procedural safety. Procedural morbidity and mortality risks have been shown to be significantly greater in those patients who have undergone stent-assisted coiling compared with those who have not undergone stent-assisted coiling. Procedural morbidity and mortality risks are significantly increased when treating ruptured aneurysms as opposed to unruptured aneurysms with a stent. Several series have recently been published that focus specifically on complex MCA aneurysms. In the largest series, Johnson et al treated 100 MCA aneurysms with stent assistance. Follow-up imaging showed complete occlusion in 90.6% of aneurysms, residual neck in 3.5%, and residual filling in 5.9%. Four aneurysms (4.7%) required re-treatment. Long-term MRA follow-up revealed stability or progressive thrombosis in 97.9%. Permanent morbidity was seen in 1% and mortality in 1%. These authors suggested that this treatment method represented a safe and acceptable alternative to craniotomy.

Intra-aneurysmal flow diverters now represent an additional treatment option for wide-neck bifurcation aneurysms. Pierot et al treated 34 ruptured and unruptured MCA aneurysms with the WEB device. Adequate occlusion (total occlusion or neck remnant) was observed in 83.3% of aneurysms with an acceptable safety profile; mortality rate of the treatment was 0.0% and morbidity rate was 3.1% (intraoperative rupture with an mRS of 3 at 1-month follow-up).

**Long-Term Follow-Up, Re-Treatment, and Surgical Occlusion Rates: Do They Confer a Long-Term Advantage?**

In the present series, 4.3% were re-treated. In other endovascular series of at least 50 patients, re-treatment rates varied from 2.4%–13.9%. It is well recognized that the decision to re-treat is highly variable. Our cohort had no additional morbidity or mortality relating to the additional procedures, and in line with previous findings, the risk for further coil embolization did not negate the advantage of the initial embolization. At late follow-up, including re-treated aneurysms, 157 of 158 aneurysms showed complete occlusion, neck remnant, or stable aneurysmal remnant. One case showed significant delayed anatomic deterioration.

Surgical series have shown high rates of complete occlusion. Each of the series published since ISAT have claimed excellent rates of initial complete aneurysm obliteration ranging from 89%-98.3%. Long-term angiographic follow-up was available in only 22% and 29% in 2 of these series but reported excellent rates of complete occlusion ranging from 96%-98%. This is perhaps one of the principal arguments for clipping aneurysms at any location; many of the reservations in the neurosurgical literature regarding the use of coiling stem from the lower rate of complete occlusion. A major limitation of this study was the lack of long-term morbidity data, and therefore, based on our data, long-term efficacy was unclear. However, the risk for rerupture occurs mostly within the first year. Beyond this, the risk lies between 0.11% and 0.21% per year. Both ISAT and CARAT (Cerebral Aneurysm Rerupture After Treatment), and BRAT (Barrow Ruptured Aneurysm Trial) studies have suggested that the benefits of coiling are unlikely to be superseded by the risk of delayed hemorrhage. The predicted risk has been calculated from the CARAT study, in which 57% showed a neck remnant, and ISAT, in which 27% showed a neck remnant. Prospectively acquired, independently assessed anatomic data have suggested that the neck remnant rate is not significantly different for MCA aneurysms vs other locations, and re-treatment rates, both in our own series and on systematic review of the literature, are not in excess of re-treatment rates at all anatomic locations. Therefore, the argument that endovascular MCA occlusion rates are low and result in a greater risk of rebleeding is unlikely to be true. The data from both CARAT and ISAT also raise the question of how aggressively to manage stable neck remnants. Most of these remnants are likely to be benign. We have noted a trend to manage neck remnants conservatively. This trend may be reflected in the proportion of re-treated patients in the more recent Cerecyte and HELPS (HydroCoil Endovascular Aneurysm Occlusion and Packing Study) trials compared with ISAT (5.5% and 3%, respectively, vs 17%).

**Morbidity and Mortality Outcomes**

Aneurysmal perforation was seen in 5% of patients, with permanent morbidity and mortality relating to this at 3%. The perforation rate lies within the range of previously published studies that have demonstrated procedural perforation complicating 1%–8.5% of MCA aneurysm treatments. In 2 large prospective series of unruptured aneurysms (ATENA) and ruptured aneurysms (CLARITY) treated by endovascular means, the perforation rate for MCA aneurysms was 4.1% and 8.5%, respectively. We have previously suggested that the rate of aneurysmal perforation may be higher at the MCA location; we demonstrated that MCA aneurysms accounted for 13% of cases but 24% of all intraprocedural ruptures. In the CLARITY study, the frequency of procedural perforation was significantly higher in the MCA group compared with aneurysms at other locations, though the cumulative morbidity and mortality rates of procedural perforation were not significantly increased.

The thromboembolic rate was 6%, with permanent morbidity and mortality rate relating to this at 3%. This rate is lower than in many large endovascular series and in prospective series that demonstrate thromboembolism complicating 7%–19.6%. We attributed this finding, at least in part, to the routine use of intravenous aspirin and low use of adjunctive devices, particularly stents. In other series, aspirin administration was not routine with ruptured aneurysms that comprised most aneurysms in this series. In the CLARITY study, although the rate of thromboembolic complications was not significantly higher in MCA aneurysms compared with those at other locations, the cumulative morbidity and mortality rate related to thromboembolic events was significantly higher in the MCA group than in the non-MCA group (7.5% vs 3.3%, respectively; P = .038). Therefore, it was
suggested that the clinical consequences of thromboembolism are important because of the size and function of the MCA territory.

In this study, 3 patients (1.2%) experienced rebleeds and all died. All aneurysms appeared completely occluded on postprocedure angiography, and all occurred within the first 24 hours of the procedure. The CARAT study demonstrated a risk of rebleeding at all anatomic locations after complete occlusion by use of coiling to be 1.8% and clipping to be 0.9%. It appears, therefore, that the results for MCA aneurysm coiling are not dissimilar to those for all locations.

**Surgical Morbidity and Mortality**

Published single-center surgical series specifically focusing on ruptured MCA aneurysms have variably reported procedural complication rates. Two recent series have described complication rates. Güresir et al described infarction complicating 5.5% of cases and peri-procedural hemorrhage complicating 5.5% of cases in their series of 168 cases. Rodriguez-Hernández et al reported the procedural-related combined morbidity and mortality to be 1.1% in a series of 282 ruptured MCA aneurysms. Intra-procedural rupture occurred in 7.5%, but there was no permanent morbidity or mortality relating to this. These results are very impressive and reflect a highly specialized service, but we do question whether they can be generalized to the neurosurgical community as a whole, particularly to centers with modest volume. Indeed, data base analysis of a large US population (2454 patients) with ruptured aneurysms from 2006–2011 at multiple centers demonstrated that patients treated with clipping demonstrated an increased likelihood of morbidity, as defined by hospital discharge to long-term care facilities, ischemic complications, and other postoperative complications, compared with patients treated with coiling. Prospective data on procedural morbidity and mortality relating to ruptured MCA aneurysm clipping are lacking, but data from the PRESAT (Prospective Registry of Subarachnoid Aneurysms Treatment) trial (40.5% of surgical cases were MCA aneurysms) show an overall clipping-related complication rate of 17.2%. This rate included intraoperative rupture in 6.7%, ischemic complications in 6%, and hemorrhagic complications in 5.4% (the latter included parenchymal contusions, extradural and subdural hematomas, and primary hematoma extension).

An additional potential drawback of the use of open neurosurgery is the risk for epilepsy. This finding was not assessed in the present series, but in late follow-up of ISAT, it has been demonstrated that MCA location is associated with an increased epilepsy risk for both coiling and clipping but that this risk is significantly greater in patients who had undergone clipping. In the clipping group, the risk for epilepsy at 1 year was 2.6% for non-MCA locations compared with 6.5% for MCA aneurysms. At 5 years, the cumulative risk was 10.3% for the MCA location. For clipping, the risk at 1 year for non-MCA locations was 4.3%, but for MCA aneurysms, this risk was 11.5% and at 5 years, the cumulative risk was 21.7%.

**Surgical and Endovascular Treatment of Unruptured MCA Aneurysms**

A safety profile is key to an effective treatment in the elective setting. In the endovascular cohort of ISUIA (International Study of Unruptured Intracranial Aneurysms), mortality rate was 1.7% and morbidity rate (mRS, 3–5) was 2.2% in 451 patients. In our cohort of patients with unruptured aneurysms, the mortality rate was 1.8%. There was no permanent morbidity. The prospective ATENA study was not powered to compare outcomes by anatomic location, but the rate of thromboembolism and aneurysm perforation was 9.6% and 4.1%, respectively, for the MCA location and overall morbidity and mortality rate was 1.7% and 1.4%, respectively. A systematic review of 500 patients with 541 unruptured MCA aneurysms treated at 12 centers by EVC demonstrated a permanent procedural morbidity rate of 5.1% and a mortality rate of 0.3%. ATENA also demonstrated no difference in anatomic occlusion between the MCA and other anterior circulation aneurysms.

For unruptured aneurysms, several large surgical series from high-volume centers have demonstrated an excellent procedural safety profile, with morbidity rates ranging from 2%–6% and mortality rates from 0%–2%. In 2 studies, approximately half of all aneurysms treated were < 5 mm and most were < 10 mm in size. This characteristic may well have contributed to the good outcomes, as it is evident that increasing age and aneurysm size are associated with increasing surgical morbidity rates. In the largest series of 263 patients with 339 aneurysms who underwent surgical clipping in 280 operations, Morgan et al assessed risk based on age and aneurysm size. Patients < 60 years old with an aneurysm ≤ 12 mm constituted a low-risk group with a procedural-related combined mortality and morbidity rate of 0.6% (95% CI, 0–3.8). Patients < 60 years old with an aneurysm > 12 mm had a procedural-related combined mortality and morbidity rate of 7.4% (95% CI, 1–24.5). Patients ≥ 60 years old with an aneurysm size of ≤ 12 mm had a procedural-related combined mortality and morbidity rate of 9.3% (95% CI, 4.3–18.3). Patients ≥ 60 years old with an aneurysm size of > 12 mm had a procedural-related combined mortality and morbidity rate of 22.2% (95% CI, 8.5–45.8).

These data suggest a good safety profile for small aneurysms but do raise the specific question of whether EVC would be more appropriate for older patients with larger aneurysms. Furthermore, whether the results of these surgical series can be extrapolated to general neurosurgical practice is questionable. Multi-center data are limited, but one source is the ISUIA study. MCA aneurysms comprised 29% of the prospective ISUIA cohort, and surgical-related morbidity and mortality was seen in 13.7% of patients. International Classification of Diseases code data base analysis of 2535 patients with unruptured aneurysms treated between 1998 and 2000 demonstrated that EVC was associated with fewer adverse outcomes (6.6% vs 13.2%), decreased mortality rates (0.9% vs 2.5%), and shorter lengths of hospital stay (4.5 vs 7.4 days). Using a similar, but larger data base analysis of patients treated between 2001 and 2008, Brinjikji et al showed that the percentage of patients discharged from the hospital to long-term facilities was 14.0% (4184/29,918) for patients who underwent clipping compared with 4.9% (1655/34,125) of patients who were treated with coiling (P < .0001). Patients who received clipping also had a higher mortality rate because 344 (1.2%) of these patients died compared with 215 (0.6%) of patients who received coiling (P < .0001).
CONCLUSIONS

Most MCA aneurysms can be effectively treated with EVC, achieving satisfactory rates of occlusion with acceptable safety profiles and rates of favorable outcome. For ruptured aneurysms, clinical results are similar to those for aneurysms at other locations and also to those achieved in many surgical series. The clinical and anatomic results of this series are also similar to those of a recently published systematic review, suggesting that they are repeatable. Recurrence is, not unexpectedly, more common in giant, large, and wide-neck aneurysms, but results of prospective trials suggest that anatomic results are not dissimilar to other anatomic locations. Therefore, the endovascular approach to MCA aneurysms is justifiable.

Disclosures: Marcus Bradley—UNRELATED: Grants/Grants Pending: Covidien,* Comments: Funding for nurses and trainees in the form of an educational grant; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Travel and accommodation expenses from ev3 for attendance at a meeting regarding the Pipeline device in 2012 (expenses paid directly) Travel and accommodation expenses for attendance at the American Society of Neuroradiology meeting in 2011 covered by ev3 (expenses paid directly); Other: Meals provided by Stryker during attendance at biannual morbidity and mortality meetings. Andrew Molyneux—UNRELATED: Consultancy: Sequent Medical, Comments: Current agreement, but postdated the case series. Shelley Renowden—UNRELATED: Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Travel expenses/accommodation paid by Stryker and Covidien to overseas meetings. *Money paid to institution.

REFERENCES


